Olympus Corp
TSE:7733

Watchlist Manager
Olympus Corp Logo
Olympus Corp
TSE:7733
Watchlist
Price: 2 458.5 JPY -0.79% Market Closed
Market Cap: 2.9T JPY
Have any thoughts about
Olympus Corp?
Write Note

Olympus Corp
Cash & Cash Equivalents

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Olympus Corp
Cash & Cash Equivalents Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash & Cash Equivalents CAGR 3Y CAGR 5Y CAGR 10Y
Olympus Corp
TSE:7733
Cash & Cash Equivalents
ÂĄ274.4B
CAGR 3-Years
18%
CAGR 5-Years
19%
CAGR 10-Years
1%
Terumo Corp
TSE:4543
Cash & Cash Equivalents
ÂĄ194.9B
CAGR 3-Years
-1%
CAGR 5-Years
11%
CAGR 10-Years
6%
Sysmex Corp
TSE:6869
Cash & Cash Equivalents
ÂĄ91.7B
CAGR 3-Years
5%
CAGR 5-Years
10%
CAGR 10-Years
9%
Nihon Kohden Corp
TSE:6849
Cash & Cash Equivalents
ÂĄ32.5B
CAGR 3-Years
2%
CAGR 5-Years
12%
CAGR 10-Years
9%
JEOL Ltd
TSE:6951
Cash & Cash Equivalents
ÂĄ39.6B
CAGR 3-Years
7%
CAGR 5-Years
36%
CAGR 10-Years
15%
Fukuda Denshi Co Ltd
TSE:6960
Cash & Cash Equivalents
ÂĄ62.4B
CAGR 3-Years
4%
CAGR 5-Years
5%
CAGR 10-Years
11%
No Stocks Found

Olympus Corp
Glance View

Market Cap
2.9T JPY
Industry
Health Care

Olympus Corp., a global leader in optical and digital precision technology, has carved a remarkable niche in the healthcare and life sciences sectors. Founded in Japan in 1919, the company initially focused on cameras and microscopes but has since evolved into a dominant player in the medical device arena, particularly known for its innovative imaging systems, endoscopy equipment, and surgical solutions. Olympus's commitment to enhancing healthcare outcomes is underscored by its significant investments in research and development, enabling the company to deliver cutting-edge solutions that improve patient care and empower healthcare professionals. With a strong presence in over 40 countries, Olympus not only addresses prevailing healthcare challenges but also actively participates in the global push toward minimally invasive procedures, thereby appealing to a growing segment of health-conscious patients and cost-sensitive healthcare systems. For investors, Olympus Corp. presents an intriguing opportunity characterized by resilient financial performance and strategic growth initiatives. The company has consistently demonstrated robust revenue generation, bolstered by its leadership in the endoscopy market, which accounts for a substantial portion of its sales. Furthermore, Olympus is strategically focused on expanding its product offerings through acquisitions and collaborations, reinforcing its commitment to innovation. The growing demand for minimally invasive surgeries, driven by advances in technology and patient preferences, positions Olympus favorably for future growth. With its solid foundation, continuous evolution, and commitment to sustainability, Olympus Corp. stands as a compelling investment option for those looking to align with a company dedicated to transforming healthcare and enhancing lives.

Intrinsic Value
2 702.13 JPY
Undervaluation 9%
Intrinsic Value
Price

See Also

What is Olympus Corp's Cash & Cash Equivalents?
Cash & Cash Equivalents
274.4B JPY

Based on the financial report for Jun 30, 2024, Olympus Corp's Cash & Cash Equivalents amounts to 274.4B JPY.

What is Olympus Corp's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 10Y
1%

Over the last year, the Cash & Cash Equivalents growth was -51%. The average annual Cash & Cash Equivalents growth rates for Olympus Corp have been 18% over the past three years , 19% over the past five years , and 1% over the past ten years .

Back to Top